A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.
Portland Veterans Affairs Medical Center, P3 R&D, Portland, OR, USA. email@example.com, , , , ,
Analysis of Variance
Enzyme-Linked Immunosorbent Assay
Pub Type(s)Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.